PTC Therapeutics Adds Biotech Banking Veteran Jessica Chutter to Board
Event summary
- PTC Therapeutics appointed Jessica Chutter, former Morgan Stanley biotech banking head, to its Board of Directors on March 25, 2026.
- Chutter oversaw $165 billion in capital raising and strategic transactions during her 40-year career at Morgan Stanley.
- She holds degrees from McGill University (BA) and Harvard University (MBA).
- PTC positions Chutter to guide its next growth phase as a rare disease-focused biopharma.
The big picture
PTC Therapeutics is bolstering its board with deep financial markets expertise as it navigates the capital-intensive rare disease space. Chutter's arrival signals intent to optimize strategic transactions and financing amid a challenging biotech funding environment. Her $165 billion deal track record suggests PTC may pursue more aggressive growth moves.
What we're watching
- Capital Strategy
- How Chutter's dealmaking expertise will shape PTC's financing approach amid biotech funding volatility.
- Growth Acceleration
- Whether her strategic transaction experience can unlock new partnerships or acquisitions for PTC's rare disease pipeline.
- Board Dynamics
- The pace at which Chutter influences governance structure as PTC transitions to its next operational phase.
Our editorial coverage:
Related topics